{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:45:43Z","timestamp":1793317543744,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.lungcan.2022.11.009","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T22:51:17Z","timestamp":1668639077000},"page":"47-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study"],"prefix":"10.1016","volume":"175","author":[{"given":"Janakiraman","family":"Subramanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha B.","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-La","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teh-Ying","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Gregg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Silvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Makin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liane","family":"Gillespie\u2013Akar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliki","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen A","family":"Kahangire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiyan","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Navani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2022.11.009_b0005","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semcancer.2020.07.009","article-title":"Precision medicine in non-small cell lung cancer: current applications and future directions","volume":"84","author":"Yang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.lungcan.2022.11.009_b0010","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2022.11.009_b0015","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.11.009_b0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/annonc\/mdy554","article-title":"Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS","volume":"30","author":"Wu","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.11.009_b0025","unstructured":"P.M. Ellis, E.T. Vella, Y.C. Ung, Systemic treatment for patients with advanced non-small cell lung cancer, Toronto (ON), Cancer Care Ontario (2016 November 14) [Being Updated 2018 Dec]. Program in Evidence-Based Care Guideline No.: 7\u201310 Version 3 Being updated."},{"key":"10.1016\/j.lungcan.2022.11.009_b0030","doi-asserted-by":"crossref","unstructured":"M.A. Socinski, T. Evans, S. Gettinger, T.A. Hensing, L. VanDam Sequist, B. Ireland, T.E. Stinchcombe, Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines, Chest 143 (2013) (5 suppl) e341S\u2013e368S. https:\/\/doi.org\/10.1378\/chest.12-2361.","DOI":"10.1378\/chest.12-2361"},{"key":"10.1016\/j.lungcan.2022.11.009_b0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2022.11.009_b0040","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/biom9110668","article-title":"FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management","volume":"9","author":"Solassol","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.lungcan.2022.11.009_b0045","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/ijms20010146","article-title":"First- and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-na\u00efve EGFR mutation-positive non-small cell lung cancer?","volume":"20","author":"Takeda","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2022.11.009_b0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jmoldx.2013.03.001","volume":"15","author":"Lindeman","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.lungcan.2022.11.009_b0055","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2022.11.009_b0060","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"ADAURA Investigators, Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2022.11.009_b0065","first-page":"1","article-title":"Clinical use of epidermal growth factor receptor testing in patients with advanced lung cancer by physicians: survey of US and international patterns","volume":"5","author":"Peters","year":"2019","journal-title":"J. Glob. Oncol."},{"key":"10.1016\/j.lungcan.2022.11.009_b0070","doi-asserted-by":"crossref","unstructured":"J.B. Adizie, J. Tweedie, A. Khakwani, E. Peach, R. Hubbard, N. Wood, J.R. Gosney, S.V. Harden, P. Beckett, S. Popat, N. Navani, Biomarker testing for people with advanced lung cancer in England, J.T.O. Clin. Res. Rep. 2 (2021) 100176. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100176.","DOI":"10.1016\/j.jtocrr.2021.100176"},{"key":"10.1016\/j.lungcan.2022.11.009_b0075","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1183\/13993003.01157-2015","article-title":"Inequalities in lung cancer: a world of EGFR","volume":"47","author":"Carbonnaux","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2022.11.009_b0080","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/EDBK_237863","article-title":"Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices","volume":"39","author":"Pennell","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.lungcan.2022.11.009_b0085","first-page":"1","article-title":"Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non\u2013small-cell lung cancer using a decision analytic model, J.C.O. Precision","volume":"3","author":"Pennell","year":"2019","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.lungcan.2022.11.009_b0090","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3747\/co.27.7297","article-title":"Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR-mutated non-small-cell lung cancer","volume":"27","author":"Cheema","year":"2020","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lungcan.2022.11.009_b0095","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/curroncol28020102","article-title":"Improvement of EGFR testing over the last decade and impact of delaying TKI initiation","volume":"28","author":"Blanc-Durand","year":"2021","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lungcan.2022.11.009_b0100","doi-asserted-by":"crossref","unstructured":"B.H.L. Goulart, S. Chennupati, C.R. Fedorenko, S.D. Ramsey, Access to tyrosine kinase inhibitors and survival in patients with advanced EGFR+ and ALK+ positive non-small-cell lung cancer treated in the real-world, Clin. Lung Cancer 22 (2021) e723\u2013e733. https:\/\/doi.org\/10.1016\/j.cllc.2021.01.019.","DOI":"10.1016\/j.cllc.2021.01.019"},{"key":"10.1016\/j.lungcan.2022.11.009_b0105","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/JTO.0b013e3181b27b15","article-title":"Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status","volume":"4","author":"Ou","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2022.11.009_b0110","doi-asserted-by":"crossref","unstructured":"J.C. Lee, Y. Kim, S.Y. Lee, S.S. Yoo, K. Davis, S.P. Nagar, W. Sawyer, N. Yu, A Taylor, South Korean real-world treatment patterns in patients with EGFRm NSCLC, Annal. Oncol. 31 (2020) (suppl 6) S1386\u2013S1406, 413P. https:\/\/doi.org\/10.1016\/annonc\/annonc367.","DOI":"10.1016\/j.annonc.2020.10.407"},{"key":"10.1016\/j.lungcan.2022.11.009_b0115","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3389\/fonc.2020.01481","article-title":"An observational study of acquired EGFR T790M-dependent resistance to EGFR-TKI treatment in lung adenocarcinoma patients in Taiwan","volume":"10","author":"Wu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2022.11.009_b0120","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40801-021-00261-8","article-title":"European and US real-world treatment patterns in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: a retrospective medical record review","volume":"8","author":"Shah","year":"2021","journal-title":"Drugs Real World Outcomes"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222006821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222006821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:02:33Z","timestamp":1759237353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222006821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":24,"alternative-id":["S0169500222006821"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.11.009","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}